Rasch MR et al. |
Chains, sheets, and droplets: assemblies of hydrophobic gold nanocrystals with saturated phosphatidylcholine lipid and squalene. |
2012 |
Langmuir |
pmid:23033891
|
Singh M et al. |
MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine. |
2012 |
Hum Vaccin Immunother |
pmid:22832252
|
Vesikari T et al. |
Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age. |
2012 |
Hum Vaccin Immunother |
pmid:22906943
|
Della Cioppa G et al. |
Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults. |
2012 |
Hum Vaccin Immunother |
pmid:22426371
|
Faenzi E et al. |
One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies. |
2012 |
Vaccine |
pmid:22521851
|
Hatz C et al. |
A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. |
2012 |
Vaccine |
pmid:22626675
|
Hwang SM et al. |
Comparison of the adverse events associated with MF59-adjuvanted and non-adjuvanted H1N1 vaccines in healthy young male Korean soldiers. |
2012 |
Jpn. J. Infect. Dis. |
pmid:22627298
|
Siegrist CA et al. |
Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine. |
2012 |
Antivir. Ther. (Lond.) |
pmid:22544169
|
Yang M et al. |
MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice. |
2012 |
Int. Immunopharmacol. |
pmid:22595192
|
Cabrera-Vique C et al. |
Bioactive compounds and nutritional significance of virgin argan oil--an edible oil with potential as a functional food. |
2012 |
Nutr. Rev. |
pmid:22537213
|
Stella B et al. |
Nonpolymeric nanoassemblies for ocular administration of acyclovir: pharmacokinetic evaluation in rabbits. |
2012 |
Eur J Pharm Biopharm |
pmid:22008147
|
Nakazawa A et al. |
Optimization of culture conditions of the thraustochytrid Aurantiochytrium sp. strain 18W-13a for squalene production. |
2012 |
Bioresour. Technol. |
pmid:22023965
|
Sancho A et al. |
More on influenza vaccine in young children. |
2012 |
N. Engl. J. Med. |
pmid:22738111
|
Yang P et al. |
Two concise enantioselective total syntheses of (-)-glabrescol implicate alternative biosynthetic pathways starting from squalene. |
2012 |
Org. Lett. |
pmid:22817611
|
RamÃrez-Torres A et al. |
Proteomics and gene expression analyses of squalene-supplemented mice identify microsomal thioredoxin domain-containing protein 5 changes associated with hepatic steatosis. |
2012 |
J Proteomics |
pmid:22796066
|
Surls J et al. |
Increased membrane cholesterol in lymphocytes diverts T-cells toward an inflammatory response. |
2012 |
PLoS ONE |
pmid:22723880
|
Girod A et al. |
Composition of fingermark residue: a qualitative and quantitative review. |
2012 |
Forensic Sci. Int. |
pmid:22727572
|
Sarpietro MG et al. |
Squalenoyl prodrug of paclitaxel: synthesis and evaluation of its incorporation in phospholipid bilayers. |
2012 |
Int J Pharm |
pmid:22728161
|
Wu S et al. |
Engineering triterpene metabolism in tobacco. |
2012 |
Planta |
pmid:22729821
|
Langley JM et al. |
Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity. |
2012 |
Pediatr. Infect. Dis. J. |
pmid:22801094
|
Block SL et al. |
Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children. |
2012 |
Pediatr. Infect. Dis. J. |
pmid:22481427
|
Sémiramoth N et al. |
Self-assembled squalenoylated penicillin bioconjugates: an original approach for the treatment of intracellular infections. |
2012 |
ACS Nano |
pmid:22482704
|
Langley JM et al. |
Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study. |
2012 |
Vaccine |
pmid:22469860
|
Fukase H et al. |
Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. |
2012 |
Vaccine |
pmid:22472791
|
Suthiwong J et al. |
A new phenolic compound from the stem of Hymenocardia wallichii. |
2012 |
J Asian Nat Prod Res |
pmid:22423644
|
RamÃrez-Torres A et al. |
Proteomics and gene expression analyses of mitochondria from squalene-treated apoE-deficient mice identify short-chain specific acyl-CoA dehydrogenase changes associated with fatty liver amelioration. |
2012 |
J Proteomics |
pmid:22402057
|
Tronchoni J et al. |
Lipid composition of wine strains of Saccharomyces kudriavzevii and Saccharomyces cerevisiae grown at low temperature. |
2012 |
Int. J. Food Microbiol. |
pmid:22405355
|
Fox CB et al. |
Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions. |
2012 |
AAPS PharmSciTech |
pmid:22415641
|
Nassim C et al. |
Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age. |
2012 |
Pediatr. Infect. Dis. J. |
pmid:22418661
|
Fox CB et al. |
Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines. |
2012 |
Clin. Vaccine Immunol. |
pmid:22896687
|
Reynales H et al. |
A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic. |
2012 |
Vaccine |
pmid:22902681
|
Naziri E et al. |
Recovery of squalene from wine lees using ultrasound assisted extraction-a feasibility study. |
2012 |
J. Agric. Food Chem. |
pmid:22888984
|
Czajka H et al. |
A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects. |
2012 |
J Prev Med Hyg |
pmid:23362618
|
Dorea JG |
Safety of thimerosal in vaccines: for whom and how many doses? |
2011 Mar-Apr |
Therapie |
pmid:23189333
|
Kozlov VG and Viktorova EG |
[Evaluation of the efficiency and reactogenicity of emulsion-based adjuvant systems in the manufacture of polyclonal enteroviral diagnostic sera]. |
2011 Mar-Apr |
Vopr. Virusol. |
pmid:21545042
|
Durando P et al. |
Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. |
2011 Jan-Feb |
Hum Vaccin |
pmid:21245655
|
Schellenberger MT et al. |
Evaluation of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene. |
2011 Jan-Feb |
Hum Vaccin |
pmid:21245662
|
Brasser AJ et al. |
Presence of wax esters and squalene in human saliva. |
2011 |
Arch. Oral Biol. |
pmid:21247555
|
Arguedas A et al. |
Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. |
2011 |
Hum Vaccin |
pmid:21285531
|
Manuel O et al. |
Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. |
2011 |
Clin. Infect. Dis. |
pmid:21288852
|
Andrews NJ et al. |
Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. |
2011 |
Vaccine |
pmid:21875635
|
Vesikari T et al. |
Oil-in-water emulsion adjuvant with influenza vaccine in young children. |
2011 |
N. Engl. J. Med. |
pmid:21995388
|
Della Cioppa G et al. |
Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. |
2011 |
Vaccine |
pmid:21906647
|
Fox CB et al. |
Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. |
2011 |
Vaccine |
pmid:21906648
|
Zuccotti GV et al. |
Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus. |
2011 |
Diabet. Med. |
pmid:21916971
|
Weyermann C et al. |
Initial results on the composition of fingerprints and its evolution as a function of time by GC/MS analysis. |
2011 |
J. Forensic Sci. |
pmid:20707835
|
Meier S et al. |
Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. |
2011 |
Vaccine |
pmid:21419775
|
Réjiba S et al. |
Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. |
2011 |
Nanomedicine |
pmid:21419876
|
Banzhoff A et al. |
Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. |
2011 |
Hum Vaccin |
pmid:21422814
|
Parretta E et al. |
Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. |
2011 |
Vaccine |
pmid:21406267
|